Company Performance Metrics
- Bernhard Günther: Founder and PresidentPast Role: Novaliq, Chief Innovation Officer
- Oliver Schlüter: Managing Director and CFOPast Role: CureVac, Chief Financial Officer
Novaliq is a pharmaceutical company focusing on the development and commercialization of first- and best-in-class ocular therapeutics based on EyeSol®, the first and only water-free technology worldwide for ophthalmology products. With an initial focus on dry eye disease (DED), Novaliq offers an industry-leading portfolio addressing today’s unmet
medical needs of millions of patients with eye diseases.
Two EyeSol® entities have been developed to distinctly target either predominantly aqueous or evaporative disease and potentially break the vicious circle of DED. Both are currently in phase 3 development:
>> NOV03 (100% perfluorohexyloctane) is the first drug developed to treat evaporative DED associated with Meibomian gland dysfunction in a highly effective way. >> CyclASol®, an ophthalmic solution of 0.1% cyclosporine A in EyeSol®, is an anti-inflammatory and immunomodulating drug for the treatment of aqueous deficient DED. Both investigational drugs have shown superior clinical benefit, with an early onset of action and an excellent tolerability profile.
NovaTears® water-free eye drops for dry eye disease have CE Marking and are commercialized in Australia/New Zealand by AFT Pharmaceuticals and in Europe as EvoTears® by Ursapharm. Novaliq is headquartered in Heidelberg, Germany and has an office in Cambridge, MA, USA.
The long-term shareholder is dievini Hopp BioTech Holding, an active investor in Life and Health Sciences companies.
More on www.novaliq.com.
